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ABSTRACT
Introduction: Transverse myelitis (TM) is an immune-
mediated disorder of the spinal cord which causes
motor and sensory disturbance and limited recovery in
50% of patients. Standard treatment is steroids, and
patients with more severe disease appear to respond to
plasma exchange (PLEX). Intravenous immunoglobulin
(IVIG) has also been used as an adjunct to steroids,
but evidence is lacking. We propose the first
randomised control trial in adults and children, to
determine the benefit of additional treatment with IVIG.
Methods and analysis: 170 adults and children aged
over 1 year with acute first episode TM or neuromyelitis
optica (with myelitis) will be recruited over a 2.5-year
period and followed up for 12 months. Participants
randomised to the control arm will receive standard
therapy of intravenous methylprednisolone (IVMP). The
intervention arm will receive the above standard therapy,
plus additional IVIG.
Primary outcome will be a 2-point improvement on
the American Spinal Injury Association (ASIA)
Impairment scale at 6 months postrandomisation by
blinded assessors. Additional secondary and tertiary
outcome measures will be collected: ASIA motor and
sensory scales, Kurtzke expanded disability status scale,
International Spinal Cord Injury (SCI) Bladder/Bowel
Data Set, Client Services Receipt Index, Pediatric Quality
of Life Inventory, EQ-5D, SCI Pain and SCI Quality of
Life Data Sets. Biological samples will be biobanked for
future studies. After 6-months’ follow-up of the first 52
recruited patients futility analysis will be carried out.
Health economics analysis will be performed to
calculate cost-effectiveness. After 6 months’ recruitment
futility analysis will be performed.
Ethics and dissemination: Research Ethics
Committee Approval was obtained: 14/SC/1329. Current
protocol: v3.0 (15/01/2015). Study findings will be
published in peer-reviewed journals.
Trial registration numbers: This study is registered
with EudraCT (REF: 2014-002335-34), Clinicaltrials.gov
(REF: NCT02398994) and ISRCTN (REF: 12127581).
INTRODUCTION
Transverse myelitis (TM) is a rare inﬂamma-
tory disorder of the spinal cord affecting
approximately 350 children and adults annu-
ally in the UK.1 2 Histologically, TM is charac-
terised by spinal cord immune cellular
inﬁltration, and pathogenesis is mediated by a
variety of immunological mechanisms.3
Clinical features include a rapid onset of
motor, sensory and autonomic dysfunction,
and a prolonged recovery phase which may
continue for up to 4 years.4 Diagnostic criteria
Strengths and limitations of this study
▪ The first randomised multicentre UK trial in chil-
dren and adults with transverse myelitis or neu-
romyelitis optica, recruiting 170 patients over
2.5 years with a 12-month follow-up period.
▪ Outcome measures will include motor, sensory,
functional and quality of life measurements by
blinded assessors.
▪ Health economics analysis will include health
and social care costs.
▪ Findings may inform treatment decisions in
other rare, inflammatory central nervous system
disorders.
▪ High recruitment rate required due to low inci-
dence of condition.
Absoud M, et al. BMJ Open 2015;5:e008312. doi:10.1136/bmjopen-2015-008312 1
Open Access Protocol
group.bmj.com on July 14, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
for TM were established by the TM Consortium Working
Group in 2002, to distinguish TM from other conditions
including MS and a clinically isolated syndrome.5 A pro-
portion of patients initially diagnosed with TM will subse-
quently relapse, often with involvement of other parts of
the central nervous system, and may often be diagnosed
with either multiple sclerosis (MS) or neuromyelitis optica
(NMO). However, a proportion of patients remain as
relapsing TM of as yet unknown aetiologies.
NMO is a relapsing subset of TM, caused by antibodies
to aquaporin-4, an astrocytic water channel.6 Clinically,
patients have predominantly recurrent episodes of myeli-
tis and optic neuritis. Initial presentation may be with
myelitis alone, making it clinically and radiologically
indistinguishable from TM, and patients are thus sub-
jected to the same acute therapeutic strategies.
The American Spinal Injury Association (ASIA) inter-
national standards for neurological classiﬁcation of
spinal cord injury enables a standardised assessment of
neurological outcome, where A is no sensory or motor
function in S4–5, and E is normal function.7
Retrospective data from paediatric cohorts suggest that
30% have ASIA A-C or expanded disability status scale
(EDSS) ≥4 after TM,8 and a retrospective French multi-
centre study in adults found that 36% had a poor prog-
nosis as deﬁned by death or non-ambulatory status with
current therapy.9 Since this is primarily a disease of
younger people, this results in signiﬁcant cumulative
demands on health and social care resources.
There are no robust controlled trials in children or
adults to inform on the optimal treatment of TM.
Standard treatment with intravenous methylpredniso-
lone (IVMP) is based on class IV evidence that it short-
ens relapse duration and speeds recovery in
exacerbations of adult multiple sclerosis.6 10–12 Given the
disease severity and poor outcomes, plasma exchange
(PLEX) has been used in addition to standard therapy.
Addition of PLEX showed beneﬁt in two studies: a retro-
spective analysis of 122 adults with TM;10 and a small
randomised controlled trial (RCT) in adults with a
steroid unresponsive acute central nervous system (CNS)
demyelination which included four patients with TM.13
However, PLEX is not universally available in the NHS,
particularly at short notice and on weekends, and can be
technically difﬁcult and costly to administer.14
Randomised controlled trials have demonstrated IVIG
efﬁcacy in a number of neurological conditions.15 In
steroid-unresponsive CNS demyelination, IVIG is often
used, although supporting data are limited to small case
series and single case reports.16 17 IVIG appears to
inhibit complement binding, neutralise pathogenic
cytokines, downregulate antibody production, enhance
remyelination and modulate phagocytosis and T-cell
function.18 The majority of these factors are common
across inﬂammatory disorders of the CNS including
TM,19 providing a strong rationale for its use. The avail-
ability, ease of administration, familiarity and safety also
make IVIG an attractive option in the acute setting.
Trial objectives and design
This multicentre, single blind, parallel group RCT will
generate evidence to inform clinical and health eco-
nomic decisions regarding IVIG use in adults and chil-
dren with TM.
Primary objective
1. To evaluate if additional and early treatment with
IVIG is of extra beneﬁt in TM when compared to the
current standard therapy of IVMP.
Secondary objectives
1. The clinical and paraclinical data collected from
patients will provide a robust resource and platform
for other clinical studies, including identiﬁcation of
early predictors of poor outcome.
2. Biobanked samples from patients recruited to the
study will be collected and used for carefully
designed biological studies by a consortium of estab-
lished basic science researchers in the ﬁeld.
METHODS
Study setting
Treatment and follow-up will be in the participating ter-
tiary neurology centres, and recruitment will also occur
from feeder district general hospitals and rapid general
practitioner (GP) referrals. For further details on partici-
pating centres and trial registration, please see online
supplementary appendix 1.
Eligibility criteria
Inclusion criteria
Patients must satisfy all inclusion criteria to be eligible
for recruitment. They will be eligible if all of the follow-
ing apply at the time of randomisation:
1. Age 1 year or over
2. Diagnosis of EITHER acute ﬁrst onset transverse mye-
litis (using the TM Consortium Working Group 2002
criteria6)—patients must fulﬁl all of the following
criteria:
i. Sensory, motor or autonomic dysfunction attribut-
able to spinal cord disease
ii. Bilateral signs and/or symptoms (not necessarily
symmetric)
iii. Sensory level (except in young children <5 years
where this is difﬁcult to evaluate)
iv. Lack of MRI brain criteria consistent with mul-
tiple sclerosis20
v. Progression to nadir between 4 h and 21 days
OR ﬁrst presentation of neuromyelitis optica (using
standardised criteria21)—patients must fulﬁl both
absolute criteria:
i. Optic neuritis
ii. Acute myelitis
plus two out of three supportive criteria (as AQP4 is
often not available acutely, only the ﬁrst two support-
ive criteria would be applied):
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i. Brain MRI not meeting criteria for MS at disease
onset
ii. Spinal cord MRI with contiguous T2-weighted
signal abnormality extending over three or more
vertebral segments, indicating a relatively large
lesion in the spinal cord
iii. Aquaporin 4 IgG seropositive status
3. ASIA Impairment Score of A-C
4. Randomisation to occur no later than day 5 of ster-
oids, and, if deﬁnitely known, within 21 days from
symptom onset.
5. Give assent (8–16 years)/consent to participate in
the trial.
Exclusion criteria
In addition to failing to meet the inclusion criteria,
exclusion criteria include any of the following:
1. Contraindication to IVIG as stated in the product
SmPC, or receiving IVIG for other reasons
2. Previously known systemic autoimmune disease (eg,
systemic lupus erythematosus) or any evidence of sys-
temic inﬂammation during current presentation.
3. Direct infectious aetiology (eg, varicella zoster)
4. Previous episode of CNS inﬂammatory demyelination
5. Acute disseminated encephalomyelitis (ADEM)
6. Other causes of myelopathy not thought to be due to
myelitis (eg, nutritional, ischaemic, tumour, etc)
7. Other disease which would interfere with assessment
of outcome measures
8. Known pregnancy
9. Circumstances which would prevent follow-up for
12 months.
Interventions
Patients randomised to the control arm of this study will
be prescribed IVMP. Paediatric patients will receive
30 mg/kg or 500 mg/m2 capped to a maximum dose of
1 g/day for 5 days. Adult patients will be given 1 g/day
for 5 days. Clinicians may follow this with an oral steroid
taper according to local practice.
Patients randomised to the intervention arm will receive
the above standard therapy plus additional IVIG at a total
dose of 2 g/kg. Doses will be divided over 2 days (children
<41.2 kg) or 5 days (all other patients) and individual
doses may vary slightly to minimise drug wastage and
anticipate for difﬁcult intravenous access in small children.
Treatment failure will be deﬁned as no improvement
14 days after presentation and/or 5 days after comple-
tion of treatment, and will be documented. Rescue
therapy may be initiated at this point. Given the thera-
peutic effect of PLEX, treatment will be standardised to
comprise ﬁve cycles in which at least 75% of plasma
volume is exchanged, with a gap of 24–48 h between
cycles. An additional course of IVMP may be given if
there is a delay between the decision to start PLEX and
therapy initiation, at the discretion of the treating clin-
ician. The duration and intensity of neurorehabilitation
input will be recorded to enable comparison between
groups.
Outcome measures
Outcome measures have been selected to give a ‘hard’
clinical end point that will have clinical signiﬁcance, and
will be assessed at the local centre by a blinded assessor.
To minimise loss to follow-up, assessments are timed to
coincide with routine clinical follow-up. All outcome
measures are internationally accepted scales, and the
primary outcome measure is the ASIA Impairment scale,
which is used to measure disability in TM.22 A 6-month
time point has been selected, as the majority of neuro-
logical recovery is likely to have occurred by this point.
Additional data points will be taken at 3 and 12 months
to aid statistical analysis.
Primary outcome measure
1. A two point or greater improvement in the ASIA
scale (classiﬁed A-E) at 6 months postrandomisation,
when compared to baseline, will indicate a positive
outcome.
Secondary outcome measures
2. A change in the ASIA motor scale (0–100) and
sensory scale (0–112)
3. A change in the Kurtzke expanded disability status
scale (EDSS) with Neurostatus scoring
4. EQ-5D-Y (patients aged 8–12 years at presentation) or
EQ-5D-5 L (patients aged ≥13 years at presentation)
5. International SCI Quality of Life Basic Data Set
(patients aged ≥13 years)
6. Client Service Receipt Inventory (CSRI).
Tertiary outcome measures
7. International SCI Bladder/Bowel Data Set (patients
aged ≥13 years)
8. International SCI Pain Basic Data Set (patients aged
≥13 years)
9. Pediatric Quality of Life Inventory TM (PedsQL
Parent Report for Toddlers; patients aged 2–4 years)
10. Pediatric Quality of Life Inventory TM (PedsQL
Parent Report for Young Children; patients aged
5–7 years).
Participant timeline
Patients will be enrolled to the study for 1 year (table 1).
Trial duration
The project will take 3.5 years. Patient recruitment will
take place over the ﬁrst 30 months, and collection of
data will continue until 42 months.
Sample size
The power analysis has taken into account the inclusion
of a futility analysis to be undertaken after recruitment
of one-third of the target sample. We have assumed that
the proportion of participants showing a two-point
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Table 1 Timeline of trial interventions
Schedule
Treatment day (TD)
Time point (T)
T0 (Screening,
baseline and
prediagnosis tests)
T1 (Treatment and discharge)
T2 3M T3 6M T4 12M WithdrawalTD 1* TD 2 TD 3 TD 4 TD 5
Rescue
therapy† Discharge
Screening with diagnostic algorithm and core investigations
including physical examination
X
Patient information and informed consent X
Eligibility form X
Registration form X
Prediagnosis tests—for example, MRI and AQP4 X
Randomisation X
Biobank samples X X
ASIA Impairment Score (A-E) X X X X P X
ASIA Motor and Sensory Score X X X X S X
Neurostatus scoring (Kurtzke functional
systems and EDSS)
X X X S X
8–12 years EQ-5D-Y X X S X
≥13 years EQ-5D-5L X X S X
≥13 years SCI QoL Basic data set X S X
CSRI X S X
≥13 years SCI Bladder T X
≥13 years SCI Bowel T X
5–7 years Peds QL T X
2–4 years Peds QL T X
Treatment form X
Concomitant medications X X X X
Discharge form X
Rescue therapy form (if needed)† X
Relapse form (at any time point if needed)† X X X X
Adverse events‡ X X X X X
Study Status Form X X X
Withdrawal form (at any time point)† X
*Treatment day 1: IVIG treatment (if applicable) to start on the same day as randomisation. Steroids may be started up to 5 days prior to randomisation.
†Rescue therapy, relapse and withdrawal forms may only be necessary for a small subset of patients.
‡Adverse events will be collected throughout the study.
ASIA, American Spinal Injury Association; AQP4, aquaporin-4; CSRI, Client Service Receipt Inventory; EDSS, expanded disability status scale; Peds QL, Pediatric Quality of Life Inventory; P,
primary outcome measure; S, secondary outcome measure; SCI, Spinal Cord Injury; T, tertiary outcome measure.
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improvement (or greater) on the ASIA Impairment
scale will be approximately 0.5 (50%) in the control arm
and a minimum of 0.75 (75%) in the intervention arm,
based on available data from epidemiological studies.2 7
The sample size calculation is based on the conservative
assumption of no correlation between repeated mea-
sures. Under these assumptions, 76 patients per group
will provide 90% power and 5% type II errors for a two-
sided test. The sample size will be inﬂated for attrition;
on the basis of our experience and the design which
minimises loss to follow-up, we estimate 10% attrition.
This requires a recruitment of 170 patients (85 partici-
pants per arm).
The ASIA total motor score (0–100) is a secondary
outcome. Stata ‘sampsi’ indicates that using an Analysis
of Covariance with a baseline to end point correlation of
0.6, there will be 87% power to detect a difference
between the control and treatment arms of a medium to
large effect size of 0.4. Such a difference will be of clin-
ical signiﬁcance.
Recruitment plan
TM has an estimated UK incidence of 350/year, and the
study centres cover approximately half of the UK popu-
lation. Assuming a recruitment rate of 39% over a
period of 2.5 years, we would expect to recruit 170
patients. This recruitment rate is based on a patient and
public consultation within the TM society, given that
patients will be admitted with a devastating weakness,
and the control arm will be receiving standard
intervention.
Randomisation
Prior to randomisation but after consent, site staff will
register a recruit on the web-based electronic data
capture system (InferMed MACRO), hosted at the King’s
Clinical Trials Unit (KCTU). Each will be assigned a
unique study patient identiﬁcation number (PIN) by the
system. Once baseline assessments are complete, the
trained trial staff will access the KCTU randomisation
system and randomise the patient at the individual level
using stratiﬁed block randomisation by service type
(adult or child); the block will randomly vary in size.
Treatment allocation will be at a ratio of 1:1.
Randomisation will occur during ofﬁce hours when
IVIG is available. Patients eligible for trial recruitment
presenting outside of these times will be started immedi-
ately on IVMP and then randomised at the ﬁrst available
opportunity.
Blinding
Owing to the technical challenges of masking IVIG from
saline, the need for rapid recruitment and the fact that
follow-up will be many months after the event using
objective, well-deﬁned clinical end points, treatment will
not be blinded. Staff carrying out study assessments and
statistical analyses will be blinded to intervention.
Data collection methods
The Kurtzke neurological examination, ASIA Impairment
Score, ASIA Motor and Sensory Score and EDSS scores
will be completed, together with the treatment, discharge
and follow-up forms (see ﬁgure 1). All assessments should
ideally be performed by the same blinded assessor, who
may be a study physician, physiotherapist or research
nurse. All assessors will have successfully completed ASIA
and EDSS online training modules (further information is
detailed in online supplementary appendix 1). Biological
samples will be collected, processed and stored as detailed
in online supplementary appendix 3.
Withdrawal
Patients may withdraw at any time. All withdrawals from
randomised treatment will be reported. If consent is
given, any existing data or samples will be retained, and
follow-up data will continue to be collected; if not, then
a withdrawal form will be completed. The investigator
may withdraw patients from the study drug in the event
of intercurrent illness, AEs, SAEs and SUSARs, subse-
quent evidence of a different aetiology, protocol viola-
tions, cure, administrative or other reasons. All data will
be analysed on an intention-to-treat basis.
Study data
Data management
Data will be managed using the InferMed MACRO data-
base system. An electronic case report form (eCRF) will
be created using the InferMed Macro system. This
system is regulatory compliant (GCP, 21CRF11, EC
Clinical Trial Directive). The eCRF will be created in col-
laboration with the trial statisticians and the chief investi-
gator (CI) and maintained by the King’s Clinical Trials
Unit. It will be hosted on a dedicated secure server
within KCL. Source data will be entered by authorised
staff onto the eCRF with a full audit trail.
Database passwords
Database access will be strictly restricted through pass-
words to the authorised research team. The CI or dele-
gate will request usernames and passwords from the
KCTU. It is a legal requirement that passwords to the
eCRF are not shared, and that only those authorised to
access the system are allowed to do so. If new staff
members join the study, a personalised username and
password will be requested via the CI or delegate.
Identifiable data
All participant contact information data will be stored
on spreadsheets within the recruiting NHS site, which
will have restricted access from password protected com-
puters. Accrual data uploaded to the UKCRN portfolio
database will be anonymised and collated by the CI or
delegate to the CLRN. No identiﬁable data will be
entered on the eCRF or transferred to the KCTU.
Participants will be identiﬁed on the study database
using a unique code and initials. The investigator will
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maintain accurate patient records detailing observations
on each patient enrolled.
Statistical methods
Primary analysis
If the study continues to full recruitment, analyses of
effectiveness will be pragmatic, based on the intention-
to-treat (ITT) sample. The signiﬁcance level will be 5%
(two-sided) for speciﬁed analyses. The estimated effect
size and its precision (95% CIs) will be presented for all
outcomes. The main statistical analyses will establish the
effectiveness of IVIG against standard therapy at
6 months postrandomisation (see primary end points
above). To this end, linear mixed modelling (LMM) will
be employed. In such models, the binary outcome vari-
able measured at the post-treatment time points (3, 6 or
12 months) features as the dependent variable with
outcome at baseline (if applicable), stratiﬁcation factors
(service level), treatment arm and a treatment x time
interaction term included as covariates. To account for
correlation between repeated measures on the same
individual, a subject-varying random intercept will be
included. Mixed effects logistic regression can be com-
pleted using the ‘xtmelogit’ command in Stata.
There are expected to be some missing data in the
post-treatment outcome variables. The LMM analyses
are based on maximum likelihood and will provide valid
inferences under a missing at random (MAR) missing-
ness mechanism.
Secondary analyses
The secondary clinical assessments (EDSS, ASIA motor
and sensory scales, SCI data sets, PedsQL, EQ5D and
CSRI) with repeated measurements will also be ana-
lysed within a LMM framework where generalisations of
the LMM will be utilised to allow for outcomes with
non-normal data if necessary. Those measures with one
follow-up assessment will be evaluated with in a
Generalised Linear Model. The dependent variable will
feature as the outcome measure. The covariates will be
the corresponding baseline measure (if applicable),
stratiﬁcation factors and treatment group.
Exploratory moderator analyses
All analysis will be repeated considering age status (adult
or child) as a moderator in interaction with the treat-
ment group (control or intervention), allowing estimates
of treatment effect in the subpopulations to be sum-
marised.23 We will carry out further explanatory analyses
to assess the efﬁcacy of the treatment within NMO or
idiopathic TM diagnosis and further putative biological
markers by allowing for interactions with the treatment
Figure 1 Flow chart showing the process of patient recruitment, treatment and follow-up.
6 Absoud M, et al. BMJ Open 2015;5:e008312. doi:10.1136/bmjopen-2015-008312
Open Access
group.bmj.com on July 14, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
arm. When considering these moderator analyses, fol-
lowing established methods24 we will centre and ortho-
gonalise interaction terms.
Further information on the statistical analysis plan can
be found in the protocol and online supplementary
appendix 1.
Interim futility analysis
TM is a rare disease and therefore requires a multicen-
tre trial spanning several years, precluding recruitment
to other interventional studies for this cohort. As such,
an interim futility analysis will be performed after a
6-month follow-up of 52 patients. If sample sizes are
equal, the trial may be abandoned if the successes in the
intervention group are fewer than in the standard
group. The probability of abandoning the study at the
interim analysis is 0.4449 if there is no difference
between treatment groups, and 0.0201 if treatment
improves outcome. The primary trial statistician will
remain blinded to the intervention and control groups,
and therefore an additional unmasked trial statistician
will perform the interim analysis. The results will be
reviewed by the Data Monitoring Committee, which has
the ability to terminate the trial prematurely.
Economic analysis
Drug pricing data and primary care, secondary care and
social care costs will be calculated as previously
described. Costs will be combined with the primary
outcome measure in the form of a cost-effectiveness ana-
lysis. If IVIG results in higher costs and better outcome,
then an incremental cost-effectiveness ratio will be gen-
erated to show the extra cost incurred to achieve an
extra unit of improvement. Owing to the uncertainty
around results, cost-effectiveness planes and cost-
effectiveness acceptability curves will be used, with boot-
strapping of skewed results.
Long-term cost-effectiveness over 5-year and 10-year
periods will be calculated using a Markov model.
Response to treatment will be classiﬁed, and transition
probabilities between groups will be derived from
6-month and 12-month follow-up data. Costs and QALYs
for each category will be derived from the trial data. As
limited data will be available on long-term costs, we will
conduct both deterministic and probabilistic sensitivity
analyses.
All causes of withdrawal from randomised treatment
will be reported. χ2 (Fisher’s exact test) will be used for
categorical outcomes (eg, serious adverse events and
mortality).
There will be missing data in post-treatment outcome
variables as participants discontinue treatment or are
lost to follow-up. Inferences will be valid provided the
missing data generating mechanism is missing at
random (MAR), and is not predicted by any variables in
the model, that is, missingness is predicted only by vari-
ables that are included in the model.
Economic evaluation
The use of IVIG, IVMP, additional treatments and
rescue PLEX will be recorded throughout the follow-up
period and costed using drug pricing data from the
British National Formulary and the Department of
Health. Use of primary care, secondary care and social
care will be recorded at three-month, 6-month and
12-month follow-ups using the CSRI, and costs calcu-
lated to determine total cost for THE control and treat-
ment arms.
A cost-effectiveness analysis will be performed using
the primary and secondary outcome measures of
improvement in ASIA scores, and secondary outcome of
QALYs with EQ-5D-Y, EQ-5D-5L and CSRI. If IVIG
results in higher costs and better outcome, then an
incremental cost-effectiveness ratio will be generated to
show the extra cost incurred to achieve an extra unit of
improvement.
Data monitoring
The Data Monitoring Committee (DMC) will review
effectiveness and safety data during the trial to inform
their recommendations to the Trial Steering Committee
(TSC). The DMC is independent from the sponsor and
funders, and will consist of a statistician, a clinician and
a clinician scientist.
Harms
Most adverse drug reactions that occur in this study,
whether serious or not, will be expected treatment-
related side effects as IVIG has a well-established side
effect proﬁle. Monitoring and reporting of adverse
events will be performed by the site PI and research
team, and will be recorded on an eCRF and uploaded to
the InferMed MACRO database. Serious adverse events
will be reported expeditiously to the sponsor, who in
turn will inform the CI. The CI will assess SUSAR status.
If a SUSAR is detected, the CI will work with the
sponsor to report to the regulatory authorities. The CI
will report to the relevant ethics committees and DMC.
An independent TSC and DMC will convene every
6 months; the TSC’s key purpose will be to monitor
study progress and act on the recommendations of the
DMC. The DMC will aim to meet 3 weeks prior to the
TSC convening. Additional meetings will be arranged if
recommended by the DMC or TSC.
Auditing
Monitoring of this trial will ensure compliance with
Good Clinical Practice (GCP). Scientiﬁc integrity will be
managed and oversight retained by the King’s Health
Partners Clinical Trials Ofﬁce Quality Team. The investi-
gator sites will provide direct access to all trial-related
source data/documents and reports for the purpose of
monitoring and auditing by the sponsor and inspection
by local and regulatory authorities. Data will be evalu-
ated for compliance with the protocol and accuracy in
relation to source documents.
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Following written standard operating procedures, the
monitors will verify that the clinical trial is conducted
and data are generated, documented and reported in
compliance with the protocol, GCP and the applicable
regulatory requirements.
ETHICS AND DISSEMINATION
Ethical and safety considerations
This trial has been approved by the UK National
Research Ethics Service (NRES) committee (South
Central—Berkshire B; REC 14/SC/1329). Clinical trial
authorisation for a type A trial has been granted via the
Medicines and Healthcare Products Regulatory Agency
(MHRA) notiﬁcation scheme. Written approval from
the respective Research and Development (R&D)
departments will be obtained for each participating
site.
The CI will ensure that this study (and all subsequent
approved amendments) is conducted in accordance with
the principles of the Declaration of Helsinki (1996), in
full conformity with the International Conference on
Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH)
Guidelines for GCP (CPMP/ICH/135/95 July 1996), the
Research Governance Framework, and the Medicines for
Human Use (Clinical Trial) Regulations 2004.
Pharmacovigilance will be monitored by the CI, who will
report to the REC, MHRA and funders (NIHR) during
and at the end of the trial.
All protocol modiﬁcations will be disseminated to all
relevant parties.
Informed consent
A member of the trial staff will screen the patient and, if
eligible, patients will be given age appropriate patient
information sheets (PIS) explaining the trial (see online
supplementary appendix 2). Trial staff will obtain
informed written consent from patients over 16 years of
age wishing to participate. For those aged under 16,
assent will be obtained from the patient and consent
from the parents or legal guardian. At the same time,
consent will be obtained for the storage and use of par-
ticipant data and biological specimens in future studies.
Confidentiality
Only anonymised data will be entered onto the eCRF.
Source data will be retained on password-protected Trust
computers and in patient notes to protect patient
conﬁdentiality.
Access to data
The CI will control access to data.
Dissemination plan
Study ﬁndings will be presented in conferences and pub-
lished in peer-reviewed journals.
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